| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSIn Situ CarcinomaDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSIn Situ CarcinomaDISCUSSIONREFERENCES |
|---|
In an effort to obtain a more integrated understanding of vascular stroma formation in breast carcinoma, we examined mRNA expression by ISH3 on consecutive frozen sections from 113 blocks of breast tissue from 68 patients. We studied normal breast tissue, benign proliferative lesions, healing biopsy sites, in situ carcinomas, invasive carcinomas, and metastatic carcinomas. We examined expression of mRNAs for the angiogenic factor VPF/VEGF and its receptors flt-1 (VEGFR-1) and KDR (VEGFR-2), which have been reported to be up-regulated in a number of human cancers, including breast cancer (for review, see Ref. 8 ). We also studied expression of TSP-1, which has been reported to have antiangiogenic properties in a variety of systems (9, 10, 11) . We also studied the stromal components collagen type I, total fibronectin, and ED-A+ fibronectin (a spliced variant of fibronectin strongly expressed in embryonic development). Fibronectins may play an important role in vascular stroma formation because they have been reported to be essential for heart and blood vessel morphogenesis (12) , to be chemotactic for endothelial cells (13) , to modulate endothelial response to growth factors (14) , and to promote the elongation of microvessels during angiogenesis in vitro (15) . We also studied the expression of the proteoglycans decorin and versican. Decorin has been reported to bind growth factors (16 , 17) and also to decrease cell proliferation through up-regulation of p21 (18) . All tissues studied had been freshly collected and optimally prepared for mRNA ISH. Although some of these components have been studied individually in breast cancer, they have not previously been investigated in an integrated manner.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSIn Situ CarcinomaDISCUSSIONREFERENCES |
|---|
Twenty-one blocks of normal breast tissue, 2 healing biopsy sites, and 5 benign ductal proliferative lesions were examined. These sections were taken from the specimens with tumors but in areas well away from the tumor, and the absence of tumor in these sections was confirmed microscopically.
Invasive carcinoma was studied in 56 cases, including 43 invasive ductal carcinomas. Twenty-four of the invasive ductal carcinomas were grade III, 18 were grade II, and 1 was grade I. Eight invasive carcinomas with mixed ductal and lobular features, two cases of invasive lobular carcinoma, and three cases of invasive mucinous carcinoma were also studied. The mean age of patients with invasive carcinoma was 59.3 years (range, 28–97 years). The mean tumor diameter was 3.1 cm (range, 1.0–7.0 cm). Thirty-five patients were estrogen receptor positive. Eighteen patients had metastases to axillary lymph nodes. Twenty patients had identifiable lymphatic invasion.
DCIS was studied in 18 cases, LCIS was studied in 3 cases, metastatic carcinoma was studied in lymph nodes in 8 cases, and extensive carcinoma in dermal lymphatics was studied in 1 case.
ISH.
Thin (2-mm) slices of fresh breast tissue were fixed in 4% paraformaldehyde in PBS, pH 7.4 (PBS), for 2–4 h at 4°C, transferred to 30% sucrose in PBS overnight at 4°C, frozen in OCT compound (Miles Diagnostics, Elkhart, IN), and stored at -70°C.
ISH was performed on 5-µm frozen sections with 10 probes in most cases: VPF/VEGF, flt-1 (VEGFR-1), KDR (VEGFR-2), TSP-1, collagen type I, total fibronectin, ED-A+ fibronectin, decorin, versican, and a sense control probe. In a few cases, the amount of tissue was insufficient for study with all probes. The precise number of cases studied with each probe is detailed in "Results."
Details of ISH have been published previously (20) . Briefly, slides were passed through 0.2 M HCl-Tris-EDTA with 1 µg/ml proteinase K, 0.2% glycine, 4% paraformaldehyde in PBS (pH 7.4), 0.1 M triethanolamine containing 1:200 (v/v) acetic anhydride, and 2x SSC. Slides were hybridized overnight at 50°C with 35S-labeled riboprobes in the following mixture: 0.3 M NaCl, 0.01 M Tris (pH 7.6), 5 mM EDTA, 50% formamide, 10% dextran sulfate, 0.1 mg/ml yeast tRNA, and 0.01 M DTT. Posthybridization washes included 2x SSC, 50% formamide, and 10 mM DTT at 50°C; 4x SSC, 10 mM Tris, and 1 mM EDTA with 20 µg/ml RNase A at 37°C; and 2x SSC, 50% formamide, and 10 mM DTT at 65°C; and 2x SSC. Slides were then dehydrated through graded alcohols containing 0.3 M ammonium acetate, dried, coated with Kodak NTB 2 emulsion, and stored in the dark at 4°C for 2 weeks. The emulsion was developed with Kodak D19 developer, and the slides were counterstained with hematoxylin. Antisense 204-bp single-stranded 35S-labeled VPF/VEGF RNA probe and its sense control were designed by B. Berse (Beth Israel Deaconess Medical Center, Boston, MA) and have been described previously (21) . The antisense probe hybridizes specifically with a region of VPF/VEGF mRNA common to all known VPF/VEGF splicing variants. 35S-labeled single-stranded antisense probes targeted to the kinase insert regions and sense RNA probes for the VPF/VEGF receptors flt-1 (225 bp) and KDR (209 bp) were designed by R.W. Jackman (Beth Israel Deaconess Medical Center, Boston, MA) and have been described previously (22) . Probes for total fibronectin (270 bp; reacts with all forms of fibronectin) and ED-A+ fibronectin (213 bp; specific to the ED-A domain; Ref. 20 ) and collagen type 1 (600 bp; Ref. 23 ) have also been described previously. The probe for TSP-1 was 354 bp long and targeted to the 5' end of the coding region. The probe for versican was 241 bp long, and the probe for decorin was 277 bp long.
Expression of mRNA for stromal elements (collagen, total fibronectin, ED-A+ fibronectin, versican, and decorin) was often intense and was classified as strong if silver grains were obvious at low power (final magnification, x40 under the microscope), moderate if expression was not obvious under low power but could be easily detected under intermediate power (x100), and low if expression could only be detected under high power (x400). VPF/VEGF mRNA was expressed at much lower levels than mRNAs of stromal elements, and therefore, actual grain counts were performed over tumor cells. VPF/VEGF mRNA expression was rated as strong (>20 grains per cell), moderate (10–20 grains per cell), or low (<10 grains per cell). Expression of VPF/VEGF receptors was even less intense and was graded as either strong (
5 grains per cell) or low (<5 grains per cell). All slides were exposed for 2 weeks before development.
Immunohistochemistry.
Staining for factor VIII-related antigen was performed with a rabbit polyclonal antibody (Dako Corporation, Carpinteria, CA) at a dilution of 1:250, after predigestion with pepsin, using the peroxidase-antiperoxidase technique and diaminobenzidine as the chromogen.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSIn Situ CarcinomaDISCUSSIONREFERENCES |
|---|
). Of the remaining seven cases, two contained a healing biopsy site that was 1–2 weeks old and five contained benign proliferative lesions with intraductal hyperplasia and variable surrounding inflammatory and stromal changes.
|
, expression of VPF/VEGF mRNA by epithelial cells was low in nearly all cases (Fig. 2, a and b)
. Expression of VPF/VEGF receptors in endothelial cells was low in nearly all cases (Fig. 3, a and b)
. TSP-1 mRNA was expressed in three locations in normal breast tissue: stromal cells, ducts, and lobules (by both epithelial and myoepithelial cells), and in the blood vessels (Fig. 4, a and b)
. Epithelial expression was moderate in most cases and often very focal, with some cells in a duct expressing significant levels of TSP-1 mRNA and no expression in immediately adjacent cells. In some cases, expression was predominantly seen in epithelial cells, whereas in other cases, expression was predominantly seen in myoepithelial cells. Expression of TSP-1 mRNA in blood vessels and stromal fibroblasts was moderate in most cases. Collagen type I mRNA was variably expressed by stromal cells in normal breast tissue (Fig. 5, a and b)
. Total fibronectin mRNA expression by stromal cells in normal breast tissue was much less prominent than that of type I collagen and almost all cases had only low expression (Fig. 6, a and b)
. ED-A+ fibronectin mRNA expression by stromal cells was even less prominent (Fig. 7, a and b)
, with all cases of normal breast tissue showing only focal low expression. Decorin was the most strongly expressed stromal cell mRNA in normal breast tissue (Fig. 8, a and b)
, with strong expression in most cases. Versican expression by stromal cells was low level in nearly all cases (Fig. 9, a and b)
.
|
|
|
|
|
|
|
|
|
Expression patterns were more variable in the five cases of benign proliferative lesions studied. Epithelial VPF/VEGF expression was moderate in one case and low in four cases. Expression of VPF/VEGF receptor mRNAs by endothelial cells was strong in four cases and low in one case. Both stromal cell and epithelial expression of TSP-1 mRNA were strong in two cases and moderate in three. All cases showed strong expression of collagen type 1 mRNA by stromal cells. Stromal cell expression of total fibronectin was strong in one case and moderate in the others, whereas expression of ED-A+ fibronectin was moderate in two cases and low in three. Stromal cell expression of decorin was strong in four cases and moderate in one, whereas versican expression was moderate in three cases and low in two.
Invasive Carcinoma
Invasive carcinoma was studied in 56 cases, including 43 cases of infiltrating ductal carcinoma (24 grade III, 18 grade II, and one grade I; Table 1
; H&E stain, Fig. 1b
; Factor VIII-related antigen immunostain, Fig. 1c
), 8 cases with mixed ductal and lobular features, 2 cases of infiltrating lobular carcinoma, and 3 cases of mucinous carcinoma.
Infiltrating Ductal Carcinoma.
No clear differences were seen in mRNA expression between the three grades of infiltrating ductal carcinoma, and the cases are described as a group (Table 1)
. However, only one case of grade I infiltrating ductal carcinoma was studied, and therefore, generalizations on grade I tumors are not possible.
VPF/VEGF mRNA expression by tumor cells was strong in more than half of cases (Fig. 2, c and d)
and moderate in an additional 12 cases. VPF/VEGF receptor mRNA expression was strong focally in all cases (Fig. 3, c and d)
. Expression of TSP-1 mRNA by stromal cells was strong in nearly all cases (Fig. 4, c and d)
, whereas expression of TSP-1 by tumor cells was variable. Strong stromal cell expression of collagen (Fig. 5, c and d)
, total fibronectin (Fig. 6, c and d)
, ED-A+ fibronectin (Fig. 7, c and d)
, and decorin (Fig. 8, c and d)
mRNAs was seen in nearly all cases. Versican expression was more variable (Fig. 9, c and d)
, with strong expression in 15 cases, moderate expression in 24 cases, and low expression in 2 cases.
Invasive Lobular Carcinoma and Invasive Carcinomas with Mixed Ductal and Lobular Features.
Two cases of classic invasive lobular carcinoma were studied. In one case, the pattern was very different from that of invasive ductal carcinoma, with low expression of VPF/VEGF and its receptors, TSP-1, collagen, total fibronectin, ED-A+ fibronectin, and versican mRNAs, and moderate expression of decorin.
The profile of the second case more closely resembled that of invasive ductal carcinoma, with moderate expression of VPF/VEGF and strong expression of VEGF receptors. TSP-1 was strongly expressed by the stromal cells but not the tumor cells. There was strong expression of collagen, total fibronectin, ED-A+ fibronectin, and decorin and moderate expression of versican.
Eight cases of invasive carcinoma with mixed ductal and lobular features were studied. The pattern of mRNA expression was similar to that seen in invasive ductal carcinoma: VPF/VEGF, five moderate and two low; stromal cell TSP-1, four strong and three moderate; tumor cell TSP-1, one strong, four moderate, and two low; collagen, eight strong; total fibronectin, six strong and two moderate; ED-A+ fibronectin, seven strong and one moderate; decorin, seven strong and one moderate; versican, five moderate and two low; flt-1, six strong and one low; and KDR, six strong and one low.
Mucinous Carcinoma.
Three cases of mucinous carcinoma were studied. The mRNA expression patterns were similar to those seen in invasive ductal carcinoma: VPF/VEGF, one moderate and two low; flt-1, two strong; KDR, two strong; stromal cell TSP-1, three strong; and tumor cell TSP-1, one strong, one moderate, and one low; collagen, two strong; total fibronectin, three strong; ED-A+ fibronectin, two strong and one moderate; decorin, three strong; and versican, two moderate.
|
In Situ Carcinoma |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSIn Situ CarcinomaDISCUSSIONREFERENCES |
|---|
; Factor VIII-related antigen stain, Fig. 1e
). Fourteen of these patients had invasive carcinoma, and 4 had DCIS only. In cases that contained a mixture of in situ and invasive carcinoma, labeling was considered to be associated with the DCIS only if it clearly stood out from the labeling seen in the invasive component on the slide. Eleven of the 18 DCIS cases were grade III, 6 were grade II, and 1 was grade I.
VPF/VEGF mRNA expression by the epithelial cells in DCIS was strong in nine cases (Fig. 2, e and f)
, moderate in four cases and low in five cases. Expression was increased adjacent to central necrosis in DCIS. Expression of mRNAs of the VPF/VEGF receptors (flt-1 and KDR) was evaluable in 16 cases and both receptors were expressed in similar fashion. In nine cases, strong expression of receptor mRNA was seen in endothelial cells of small vessels immediately adjacent to the DCIS, with these small vessels forming a distinct and nearly continuous rim around the DCIS (Fig. 3, e and f)
. In four cases, there was strong expression in small vessels near the DCIS, but no distinct rimming pattern was seen. In three cases, no strong expression of receptors was seen in close proximity to the DCIS.
Expression of TSP-1 was distinctive. Strong labeling, visible under low power, was seen in the basal layer of myoepithelial cells in all 18 cases examined (Fig. 4, e and f)
. Focal stromal cell expression was also noted adjacent to the DCIS.
Increased collagen (Fig. 5, e and f)
, total fibronectin (Fig. 6, e and f)
, and ED-A+ fibronectin (Fig. 7, e and f)
mRNA synthesis was detected in the stromal cells immediately adjacent to DCIS in 14 of 15 evaluable cases. In eight of these cases, a distinct rim of strong stromal expression was seen at least focally around the DCIS. In the other six cases, expression was increased adjacent to the DCIS, but a strong continuous rimming pattern was not apparent. In one case, no distinct increase in expression was seen adjacent to the DCIS in comparison to stromal expression in the admixed invasive carcinoma.
In contrast to the other stromal markers, decorin expression showed a distinct rimming pattern in only two cases (Fig. 8, e and f)
, an increase adjacent to DCIS but no distinct rimming in seven cases, and no distinct increase above surrounding stroma in nine cases. Versican had a similar pattern (Fig. 9, e and f)
, with 2 cases with rimming, 4 cases with an increase near the DCIS without distinct rimming, and 12 cases without a definite increase above surrounding stroma.
LCIS.
LCIS was present in three cases. All cases were admixed with invasive carcinoma. The pattern was quite different from that in DCIS. VPF/VEGF expression was moderate in one case and low in two cases. No distinct increase in VPF/VEGF receptor expression was seen adjacent to LCIS. Focal strong expression of TSP-1 was seen in myoepithelial cells in two of the three cases. No distinct increase in collagen, total fibronectin, ED-A+ fibronectin, decorin, or versican expression was seen adjacent to the in situ carcinoma in any of the cases.
Metastatic Carcinoma.
Eight cases of carcinoma metastatic to axillary lymph nodes were studied (H&E stain, Fig. 1f
; Factor VIII-related antigen immunostain, Fig. 1g
). Seven cases were ductal type (five grade III and two grade II), and one case had mixed ductal and lobular features (grade II). Patterns of mRNA expression were remarkably similar to those seen in invasive breast carcinomas at the primary site: VPF/VEGF, three strong, four moderate, and one low (Fig. 2, g and h)
; VPF/VEGF receptors, strong in endothelial cells in all cases (Fig. 3, g and h)
; stromal TSP-1, five strong and one moderate (Fig. 4, g and h)
; tumor cell expression of TSP-1, one strong, three moderate, and two low; collagen type I, all strong (Fig. 5, g and h)
; total fibronectin, all strong (Fig. 6, g and h)
; ED-A+ fibronectin, five strong and three moderate (Fig. 7, g and h)
; decorin, all strong (Fig. 8, g and h)
; and versican, all moderate (Fig. 9, g and h)
. Expression of all mRNAs studied decreased sharply at the border with normal lymph node tissue.
Carcinoma in Lymphatics.
Our case material included one excellent example of carcinoma cells within the dermal lymphatics of breast skin well away from the primary tumor (H&E stain, Fig. 1h
). The tumor cells strongly expressed VPF/VEGF mRNA (Fig. 2, i and j)
, and small vessels around the lymphatic spaces strongly expressed flt-1 (Fig. 3, i and j)
and KDR. TSP-1 mRNA was strongly expressed by stromal cells surrounding the lymphatics (Fig. 4, i and j)
. Stromal cells surrounding the lymphatics also strongly expressed mRNAs for collagen type I (Fig. 5, i and j)
, total fibronectin (Fig. 6, i and j)
, and ED-A+ fibronectin (Fig. 7, i and j)
and moderately expressed versican mRNA (Fig. 9, i and j)
.
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSIn Situ CarcinomaDISCUSSIONREFERENCES |
|---|
Invasive ductal carcinomas of the breast showed a remarkably consistent pattern of expression of the mRNAs studied. There was strong expression of VPF/VEGF mRNA by tumor cells and strong expression of the VPF/VEGF receptors flt-1 and KDR in the endothelial cells of small vessels in the tumor. There was also marked up-regulation of mRNAs of collagen type I, total fibronectin, ED-A+ fibronectin, versican, and TSP-1 in stromal cells. Decorin was strongly expressed in stromal cells in invasive ductal carcinomas, but strong expression of decorin was also found in stromal cells in many cases of normal breast tissue.
Of interest, the patterns of mRNA expression in DCIS were very similar to those seen in invasive carcinomas. There was strong expression of VPF/VEGF mRNA by tumor cells and strong expression of VPF/VEGF receptor mRNAs by endothelial cells in small vessels immediately adjacent to foci of DCIS. There was strong expression of mRNAs for collagen type I, total fibronectin, ED-A+ fibronectin, decorin, versican, and TSP-1 immediately adjacent to DCIS. This raises the interesting possibility that, in the progression from in situ cancer to invasive cancer, the tumor cells may not be invading into normal breast stroma but rather into a highly vascular, substantially modified stroma that the tumor cells themselves have induced. It is possible that these changes may be a prerequisite to the process of invasion.
Identical patterns of mRNA expression were also seen in metastatic carcinoma in lymph nodes. Therefore, metastatic tumor cells were not growing in the normal lymph node tissue per se but rather in a highly vascular and substantially modified stroma that tumor cells had induced locally within the lymph node. Generation of this characteristic vascular stroma may be important or even essential to tumor growth at sites of metastasis.
To our surprise, the same patterns of expression could also be seen immediately adjacent to tumor cells in dermal lymphatics of breast skin in areas away from the primary tumor. The creation of a characteristic vascular stroma appears to be initiated focally, even while the cells are in transit through the lymphatics.
Although these expression patterns may be characteristic of in situ, invasive, and metastatic breast carcinoma and critical to the formation of vascular stroma and neoplastic progression, they are not specific for malignancy. Similar patterns of expression were seen in healing biopsy sites and in some benign proliferative lesions. Increased expression of VPF/VEGF and angiogenesis have been noted in both healing wounds and certain types of inflammation (reviewed in Ref. 7 ).
VPF, also known as VEGF, is an important multifunctional angiogenic cytokine that is strongly expressed in a variety of human tumors (reviewed in Ref. 8 ). VPF/VEGF binds to endothelial cells by at least two specific cell surface tyrosine kinase receptors, flt-1 and KDR (24 , 25) . VPF/VEGF induces microvascular permeability, leading to the extravasation of plasma proteins with consequent proangiogenic stromal changes (26 , 27) . VPF/VEGF is also an endothelial cell mitogen (28, 29, 30, 31) , and it alters the synthetic profile of endothelial cells in a manner that may promote angiogenesis (32 , 33) . Angiogenesis and tumor growth have been suppressed by inhibition of VPF/VEGF or its receptors in several experimental models (34 , 35) . The consistent overexpression of mRNAs for VPF/VEGF and its receptors in the breast cancer specimens in our study indicate an important role in the formation of vascular stroma.
Increased expression of VPF/VEGF, flt-1, and KDR has been described previously in breast cancer (36) , and this study confirms and extends those findings in a much larger group of patients. VPF/VEGF expression has been correlated with both vessel count and survival in invasive breast carcinoma (37, 38, 39) and with angiogenesis in DCIS (40) .
TSP-1 has been reported to have antiangiogenic properties in a variety of systems (9, 10, 11) . Transfection of TSP-1 into breast cancer cell lines decreased angiogenesis, tumor growth, and metastasis in nude mice (41) . Increased staining for TSP-1 has been reported in the stroma of breast carcinoma (42, 43, 44) . In addition, TSP-1 mRNA was reported to be increased in invasive breast carcinoma by PCR (45) . Our results confirm these findings. There was a marked up-regulation of expression of TSP-1 mRNA by stromal cells in invasive, metastatic and in situ breast cancer compared to expression by stromal cells in normal breast tissue. We speculate that increased stromal expression of TSP-1 may be an attempt to inhibit angiogenesis induced by growth factors such as VPF/VEGF. Clearly the balance falls on the side of angiogenesis, but it is not entirely unexpected that expression of angiogenesis inhibitors should be up-regulated as well.
Increased expression of stromal components such as collagen type I (46) , proteoglycans (47, 48, 49, 50, 51) , and fibronectins (52, 53, 54, 55, 56, 57) has been described in breast cancer. Various matrix components can bind growth factors and either enhance or block their activity. For example, decorin has been reported to bind transforming growth factor-ß (16 , 17) . Decorin has also been reported to inhibit cell proliferation by up-regulation of p21, an inhibitor of cyclin-dependent kinases (18) . However, although decorin was strongly expressed by stromal cells in most tumors studied, it was also strongly expressed in most normal breast tissue that we studied.
The fibronectins are a family of alternatively spliced proteins differing in three domains in humans: ED-A, ED-B, and IIICS (58) . The fibronectin isoforms are expressed at low levels in normal adult tissues, but increased expression has been reported during wound healing, cardiac hypertrophy, liver fibrosis, pulmonary fibrosis, glomerulonephritis, and cardiac transplantation (reviewed in Ref. 59 ). Fibronectins likely play an essential role in the process of vascular stroma formation. Fibronectins have been reported to be essential for heart and blood vessel morphogenesis (12) , to be chemotactic for endothelial cells (13) , to modulate endothelial response to TGF-ß (14) , and to promote the elongation of microvessels during angiogenesis in vitro (15) . ED-A+ fibronectin has also been reported to be expressed by stromal cells in colon cancer (60) . Consistent with an important role in the formation of vascular stroma in breast cancer, total fibronectin and ED-A+ fibronectin were strongly expressed in virtually all tumors studied but only weakly expressed in normal breast tissue.
In summary, the formation of vascular stroma in breast carcinoma is a process that involves complex reciprocal interactions among tumor cells, endothelial cells, and stromal cells. Although the process is complex, a characteristic mRNA expression profile was identified in this study that was remarkably similar in carcinoma in situ, invasive carcinoma, carcinoma in lymphatic spaces, and metastatic carcinoma. This study provides insight into the process of vascular stroma formation in malignancy and the possible role that vascular stroma may play in neoplastic progression.
|
FOOTNOTES |
|---|
1 Supported by USPHS NIH Grants CA50453 and CA58845 (to H. F. D.), by grants from the Beth Israel Deaconess Medical Center Pathology Foundation, and by the Nell and Nancy Fund, a Cancer Prevention Fund supported by American Family Life Assurance Company Inc. and The Pine Mountain Benevolent Association (Cason J. Callaway, Jr., President). 
2 To whom requests for reprints should be addressed, at Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. Phone: (617) 667-4344; Fax: (617) 667-3591.
3 The abbreviations used are: ISH, in situ hybridization; VPF, vascular permeability factor; VEGF, vascular endothelial growth factor; TSP-1, thrombospondin-1; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ.
Received 8/20/98; revised 1/15/99; accepted 2/ 8/99.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSIn Situ CarcinomaDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  A. M. LeBeau, W. N. Brennen, S. Aggarwal, and S. R. Denmeade Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin Mol. Cancer Ther., May 1, 2009; 8(5): 1378 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Al-Nedawi, B. Meehan, R. S. Kerbel, A. C. Allison, and J. Rak Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR PNAS, March 10, 2009; 106(10): 3794 - 3799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Henshaw, B. Mossop, and F. Yuan Relaxin treatment of solid tumors: effects on electric field-mediated gene delivery Mol. Cancer Ther., August 1, 2008; 7(8): 2566 - 2573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pukkila, A. Kosunen, K. Ropponen, J. Virtaniemi, J. Kellokoski, E. Kumpulainen, R. Pirinen, J. Nuutinen, R. Johansson, and V.-M. Kosma High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma J. Clin. Pathol., March 1, 2007; 60(3): 267 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Kuznetsova, P. Issa, E. M. Perruccio, B. Zeng, J. M. Sipes, Y. Ward, N. T. Seyfried, H. L. Fielder, A. J. Day, T. N. Wight, et al. Versican-thrombospondin-1 binding in vitro and colocalization in microfibrils induced by inflammation on vascular smooth muscle cells J. Cell Sci., November 1, 2006; 119(21): 4499 - 4509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C L Wilson, A H Sims, A Howell, C J Miller, and R B Clarke Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr. Relat. Cancer, June 1, 2006; 13(2): 617 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Eum, Y. W. Lee, B. Hennig, and M. Toborek Interplay between Epidermal Growth Factor Receptor and Janus Kinase 3 Regulates Polychlorinated Biphenyl-Induced Matrix Metalloproteinase-3 Expression and Transendothelial Migration of Tumor Cells Mol. Cancer Res., June 1, 2006; 4(6): 361 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Naumov, E. Bender, D. Zurakowski, S.-Y. Kang, D. Sampson, E. Flynn, R. S. Watnick, O. Straume, L. A. Akslen, J. Folkman, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst, March 1, 2006; 98(5): 316 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Diaz Jr., I. Cheong, C. A. Foss, X. Zhang, B. A. Peters, N. Agrawal, C. Bettegowda, B. Karim, G. Liu, K. Khan, et al. Pharmacologic and Toxicologic Evaluation of C. novyi-NT Spores Toxicol. Sci., December 1, 2005; 88(2): 562 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Midgley and D. Kerr Bevacizumab--current status and future directions Ann. Onc., July 1, 2005; 16(7): 999 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Gallagher, Y. Bao, A. Prorock, P. Zigrino, R. Nischt, V. Politi, C. Mauch, B. Dragulev, and J. W. Fox Gene Expression Profiling Reveals Cross-talk between Melanoma and Fibroblasts: Implications for Host-Tumor Interactions in Metastasis Cancer Res., May 15, 2005; 65(10): 4134 - 4146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-B. Huang, X.-J. Zhou, J.-Y. Chen, L.-H. Zhang, K. Meng, H.-H. Ma, and Z.-F. Lu CD10-positive Stromal Cells in Gastric Carcinoma: Correlation with Invasion and Metastasis Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 245 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chen, S. Pan, T. A. Brentnall, and R. Aebersold Proteomic Profiling of Pancreatic Cancer for Biomarker Discovery Mol. Cell. Proteomics, April 1, 2005; 4(4): 523 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, E. Galardi, M. Duquette, M. Delic, J. Lawler, and S. Parangi Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model Clin. Cancer Res., March 15, 2005; 11(6): 2337 - 2344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. GRANT and R. KALLUR Structural Basis for the Functions of Endogenous Angiogenesis Inhibitors Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 399 - 417. [Abstract] [PDF]
|
|
|
|
|
|
A. Ambesi, R. M. Klein, K. M. Pumiglia, and P. J. McKeown-Longo Anastellin, a Fragment of the First Type III Repeat of Fibronectin, Inhibits Extracellular Signal-Regulated Kinase and Causes G1 Arrest in Human Microvessel Endothelial Cells Cancer Res., January 1, 2005; 65(1): 148 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Namba, J. E. Maglione, L. J.T. Young, A. D. Borowsky, R. D. Cardiff, C. L. MacLeod, and J. P. Gregg Molecular Characterization of the Transition to Malignancy in a Genetically Engineered Mouse-Based Model of Ductal Carcinoma In situ Mol. Cancer Res., August 1, 2004; 2(8): 453 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Koninger, N. A. Giese, F. F. di Mola, P. Berberat, T. Giese, I. Esposito, M. G. Bachem, M. W. Buchler, and H. Friess Overexpressed Decorin in Pancreatic Cancer: Potential Tumor Growth Inhibition and Attenuation of Chemotherapeutic Action Clin. Cancer Res., July 15, 2004; 10(14): 4776 - 4783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M J Pukkila, A S T Kosunen, J A Virtaniemi, E J Kumpulainen, R T Johansson, J K Kellokoski, J Nuutinen, and V-M Kosma Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study J. Clin. Pathol., July 1, 2004; 57(7): 735 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Poon, K. K. Chung, S. T. Cheung, C. P. Lau, S. W. Tong, K. L. Leung, W. C. Yu, G. P. Tuszynski, and S. T. Fan Clinical Significance of Thrombospondin 1 Expression in Hepatocellular Carcinoma Clin. Cancer Res., June 15, 2004; 10(12): 4150 - 4157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sengupta, S. Banerjee, N. K. Saxena, and S. K. Banerjee Thombospondin-1 Disrupts Estrogen-Induced Endothelial Cell Proliferation and Migration and Its Expression Is Suppressed by Estradiol Mol. Cancer Res., March 1, 2004; 2(3): 150 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Banerjee, I. Bhattacharyya, W. M. Lydiatt, and J. K. Vishwanatha Aberrant Expression and Localization of Decorin in Human Oral Dysplasia and Squamous Cell Carcinoma Cancer Res., November 15, 2003; 63(22): 7769 - 7776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Bachelder, E. A. Lipscomb, X. Lin, M. A. Wendt, N. H. Chadborn, B. J. Eickholt, and A. M. Mercurio Competing Autocrine Pathways Involving Alternative Neuropilin-1 Ligands Regulate Chemotaxis of Carcinoma Cells Cancer Res., September 1, 2003; 63(17): 5230 - 5233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Davies, J. Salter, M. Hills, L.-A. Martin, N. Sacks, and M. Dowsett Correlation between Cyclooxygenase-2 Expression and Angiogenesis in Human Breast Cancer Clin. Cancer Res., July 1, 2003; 9(7): 2651 - 2656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A J Rice, M A Steward, and C M Quinn Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast J. Clin. Pathol., December 1, 2002; 55(12): 921 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tuxhorn, G. E. Ayala, M. J. Smith, V. C. Smith, T. D. Dang, and D. R. Rowley Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling Clin. Cancer Res., September 1, 2002; 8(9): 2912 - 2923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Rice and C M Quinn Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast J. Clin. Pathol., August 1, 2002; 55(8): 569 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chung, R. E. Bachelder, E. A. Lipscomb, L. M. Shaw, and A. M. Mercurio Integrin ({alpha}6{beta}4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells J. Cell Biol., July 8, 2002; 158(1): 165 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Nash, M. T. Deavers, and R. S. Freedman The Expression of Decorin in Human Ovarian Tumors Clin. Cancer Res., June 1, 2002; 8(6): 1754 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Monsky, C. M. Carreira, Y. Tsuzuki, T. Gohongi, D. Fukumura, and R. K. Jain Role of Host Microenvironment in Angiogenesis and Microvascular Functions in Human Breast Cancer Xenografts: Mammary Fat Pad versus Cranial Tumors Clin. Cancer Res., April 1, 2002; 8(4): 1008 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Guidi, D. A. Berry, G. Broadwater, B. Helmchen, I. J. Bleiweiss, D. R. Budman, I. C. Henderson, L. Norton, and D. F. Hayes Association of Angiogenesis and Disease Outcome in Node-Positive Breast Cancer Patients Treated With Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil: A Cancer and Leukemia Group B Correlative Science Study From Protocols 8541/8869 J. Clin. Oncol., February 1, 2002; 20(3): 732 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Touab, J. Villena, C. Barranco, M. Arumi-Uria, and A. Bassols Versican Is Differentially Expressed in Human Melanoma and May Play a Role in Tumor Development Am. J. Pathol., February 1, 2002; 160(2): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Desnoyers, D. Arnott, and D. Pennica WISP-1 Binds to Decorin and Biglycan J. Biol. Chem., December 7, 2001; 276(50): 47599 - 47607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lawler, W.-M. Miao, M. Duquette, N. Bouck, R. T. Bronson, and R. O. Hynes Thrombospondin-1 Gene Expression Affects Survival and Tumor Spectrum of p53-Deficient Mice Am. J. Pathol., November 1, 2001; 159(5): 1949 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Heer, H. Kumar, J. R. Read, J. N. Fox, J. R. T. Monson, and M. J. Kerin Serum Vascular Endothelial Growth Factor in Breast Cancer: Its Relation with Cancer Type and Estrogen Receptor Status Clin. Cancer Res., November 1, 2001; 7(11): 3491 - 3494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Rodriguez-Manzaneque, T. F. Lane, M. A. Ortega, R. O. Hynes, J. Lawler, and M. L. Iruela-Arispe Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor PNAS, October 12, 2001; (2001) 171460498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fosslien Molecular Pathology of Cyclooxygenase-2 in Cancer-induced Angiogenesis Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 325 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Bachelder, A. Crago, J. Chung, M. A. Wendt, L. M. Shaw, G. Robinson, and A. M. Mercurio Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells Cancer Res., August 1, 2001; 61(15): 5736 - 5740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Narla, C.-L. Chen, Y. Dong, and F. M. Uckun In Vivo Antitumor Activity of Bis(4,7-dimethyl-1,10-phenanthroline) Sulfatooxovanadium(IV) {METVAN [VO(SO4)(Me2-Phen)2]} Clin. Cancer Res., July 1, 2001; 7(7): 2124 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pluen, Y. Boucher, S. Ramanujan, T. D. McKee, T. Gohongi, E. di Tomaso, E. B. Brown, Y. Izumi, R. B. Campbell, D. A. Berk, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors PNAS, March 22, 2001; (2001) 81626898. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Reeves, D. D. Edberg, and Y. Li Architectural Transcription Factor HMGI(Y) Promotes Tumor Progression and Mesenchymal Transition of Human Epithelial Cells Mol. Cell. Biol., January 15, 2001; 21(2): 575 - 594. [Abstract] [Full Text]
|
|
|
|
|
|
S. P. Gunningham, M. J. Currie, C. Han, B. A. Robinson, P. A. E. Scott, A. L. Harris, and S. B. Fox The Short Form of the Alternatively Spliced flt-4 but not Its Ligand Vascular Endothelial Growth Factor C Is Related to Lymph Node Metastasis in Human Breast Cancers Clin. Cancer Res., November 1, 2000; 6(11): 4278 - 4286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Rybarczyk and P. J. Simpson-Haidaris Fibrinogen Assembly, Secretion, and Deposition into Extracellular Matrix by MCF-7 Human Breast Carcinoma Cells Cancer Res., April 1, 2000; 60(7): 2033 - 2039. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Gasparini Prognostic Value of Vascular Endothelial Growth Factor in Breast Cancer Oncologist, April 1, 2000; 5(90001): 37 - 44. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Guidi, D. A. Berry, G. Broadwater, M. Perloff, L. Norton, M. P. Barcos, and D. F. Hayes Association of Angiogenesis in Lymph Node Metastases With Outcome of Breast Cancer J Natl Cancer Inst, March 15, 2000; 92(6): 486 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pluen, Y. Boucher, S. Ramanujan, T. D. McKee, T. Gohongi, E. di Tomaso, E. B. Brown, Y. Izumi, R. B. Campbell, D. A. Berk, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors PNAS, April 10, 2001; 98(8): 4628 - 4633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Rodriguez-Manzaneque, T. F. Lane, M. A. Ortega, R. O. Hynes, J. Lawler, and M. L. Iruela-Arispe Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor PNAS, October 23, 2001; 98(22): 12485 - 12490. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
